Hints and tips:
...As healthcare systems around the world put pressure on drug prices, pharma companies are also looking for ways to cut costs in research and development....
...Both Leqembi and Eli Lilly’s new drug donanemab target amyloid, a toxic protein that builds up in the brain, usually before significant levels of tau develop....
...Eli Lilly inked a $250mn deal with Shenzhen-based Xtalpi in May. In July, Nvidia invested $50mn in US-based Recursion. Using AI does not guarantee success....
...Pascal Soriot, AstraZeneca’s chief executive, said in February that drugmakers should not be made to pay for the “explosion” of NHS costs, while US pharma groups Eli Lilly and AbbVie quit the pricing agreement...
...Shares in Eli Lilly and Roche also gained....
...LGIM has previously co-filed shareholder proposals at Eli Lilly and Gilead Sciences to split the companies’ chair and chief executive roles....
...Drugs from rival pharma groups Eli Lilly and Roche may also enter the market earlier than expected....
...Last year, Eli Lilly agreed to collaborate with California-based Atomwise, paying $1m for each AI-discovered drug. The commercial impact of DeepMind’s triumph is not yet clear....
...The first trial using a similar approach failed over 10 years ago and many including studies by Eli Lilly and Pfizer have failed since....
...The government has vowed to tackle the price of cancer medicines, threatening revenues for multinationals such as Eli Lilly, Roche and Novartis....
...“Most of the innovative drugs being developed in China are in the me-too category,” says Lin Liang, of Eli Lilly’s Asian venture capital arm, which has poured nearly $500m into mostly Chinese start-ups since...
...The failure of the drug is the latest in a string of Alzheimer’s flops and follows high-profile setbacks in recent months for companies including Eli Lilly, Merck and Lundbeck....
...Rival Eli Lilly announced job cuts and a focus on new medicines while AstraZeneca was boosted by good news on its cancer pipeline....
...Eli Lilly of the US....
...Gradually, however, China MediTech, or Chi-Med, began building its own R&D capabilities in partnership with western drugmakers including Eli Lilly and AstraZeneca....
...China-MediTech, for example, is working with AstraZeneca and Eli Lilly, while BeiGene is paired with Merck of Germany....
...More than half the world’s top 25 drugmakers, including Novartis, Pfizer and Eli Lilly, are already working with TrialReach to build a database of clinical trials which can be searched online....
...The settlement comes a year after a jury in Louisiana awarded $9bn against Takeda and its partner Eli Lilly for concealing possible health risks linked to Actos....
...As punishment, they meted out the biggest damages award yet levied against big pharma and one of the largest against companies of any kind....
...Chi-Med, for example, is developing its colorectal cancer drug, fruquintinib, with Eli Lilly of the US and is working with AstraZeneca of the UK on another, called volitinib, for renal cell cancer....
...Domestic sales at Japan’s five biggest pharmaceuticals groups – Takeda, Astellas Pharma, Daiichi Sankyo, Eisai and Chugai Pharmaceutical – account for between 45 and 90 per cent of revenues....
...“What we’re seeing in the UK is the first manifestation of something that has been predicted for some time: the cost of these drugs is not sustainable,” says Bernard Munos, a former Eli Lilly executive and...
...An FDA warning was eventually issued but Takeda and Eli Lilly, which marketed the drug in the US, say the cancer link remains unproved....
...“Blurring the distinction between speciality/generics and large-cap pharma, we see Actavis transforming from a speciality/generic business to a full-fledged pharma company with an equal balance of brands...
...(Financial Times) “A U.S. jury ordered Takeda Pharmaceutical Co Ltd to pay $6 billion in punitive damages and Eli Lilly and Co to pay $3 billion in a case claiming that cancer risks to the diabetes drug...
International Edition